Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protein Sciences "Dumbfounded" After Committee Votes Down FluBlok

This article was originally published in The Pink Sheet Daily

Executive Summary

Cell-based seasonal influenza vaccine needs both additional safety data in general and considerably more efficacy data in older patients, FDA advisory panel says.

You may also be interested in...

Protein Sciences To Begin Selling Novel Flu Vaccine; Flublok Has Virus-Free Appeal

The trivalent vaccine can be produced much faster than traditional vaccines and could be modified to compete with quadrivalent formulations.

GSK’s Bird Flu Vaccine Approval May Hinge On Pandemic Postmarketing Study

FDA will ask its Vaccines and Related Biological Products Advisory Committee to talk about how to verify and describe the clinical benefit of the vaccine under the accelerated approval regulations.

Pediatric Meningococcal Vaccine's Approval Pathway May Work For Other Disease Areas

FDA suggests serum bactericidal antibody measurements to predict protection from meningococcal diseases in children under age 2.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts